BIO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-04-30

• Additionally, the recent escalation of regional conflicts in the Middle East has adversely affected demand and logistics in the EMEA region, particularly within our Clinical Diagnostics segment. These disruptions impacted our results during the first quarter of 2026 and, given the continued uncertai…

• (Gains) losses from change in fair market value of equity securities and loan receivable124.7 (5.4)

• An accounting policy is deemed to be critical if it affects our financial statements materially and requires subjective or complex judgments by management. An accounting estimate is deemed to be critical if it requires assumptions about matters that are highly uncertain at the time the estimate is m…

• Consolidated gross margin was 52.3% for both the first quarter of 2026 and 2025. Gross margin for the Life Science segment for the first quarter of 2026 decreased by approximately 0.3 percentage points as compared to the same period in 2025. The decrease in gross margin was primarily driven by highe…

• In March 2022, we received $1.2 billion in cash proceeds from the issuance of Senior Notes. The $400 million and $800 million Senior Notes mature in March 2027 and March 2032, respectively, and interest on the Senior Notes is 3.3% and 3.7% per annum, respectively. Interest is payable semiannually in…

相对上期删除的文字 · 来源:10-Q · 2025-10-29

• Selling, general and administrative expense31.7 30.8 33.0 32.1

• (Gains) losses from change in fair market value of equity securities and loan receivable75.8 (122.0)6.8 88.5

• An accounting policy is deemed to be critical if it affects our financial statements materially and requires subjective or complex judgments by management. An accounting estimate is deemed to be critical if it requires assumptions about matters that are highly uncertain at the time the estimate is m…

• There have been no substantial changes in our significant accounting policies during the three and nine months ended September 30, 2025, compared with the significant accounting policies described in Note 1 to the financial statements contained in our Annual Report on Form 10-K for the year ended De…

• Consolidated gross margin was 52.6% for the third quarter of 2025 compared to 54.8% for the third quarter of 2024. Gross margin for the Life Science segment and Clinical Diagnostics segment for the third quarter of 2025 decreased by approximately 1.7 percentage points and 2.5 percentage points, resp…

相对上期新增的文字 · 来源:10-Q · 2026-04-30

• Use of generative AI and other AI technologies presents risks and challenges due to the evolving nature of AI.

• We utilize artificial intelligence and machine learning technologies (“AI”), such as chatbots, assistants and automation agents, in our business operations, and we are exploring the other opportunities that AI could bring us.

• The use of AI, particularly generative AI, and the developing regulatory landscape pose risks that could expose us to liability or adversely affect our business. Integration of AI into our and our vendors’ systems (potentially without the vendor disclosing such use to us) subjects us to the risk tha…

• Complying with new laws or regulations concerning sustainability matters or climate related matters will result in increased compliance costs and create additional non-compliance risks. Failure to adequately meet our stakeholder’s expectations or comply with any such laws or regulations may result i…

• We have significant manufacturing and distribution facilities, including in the United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. Thes…

相对上期删除的文字 · 来源:10-Q · 2025-10-29

• existing customers, have difficulty attracting new customers, be exposed to claims from customers and suppliers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a…

• the market value of Sartorius ordinary shares will have an impact on the value appreciation rights acquired in connection with the Loan discussed in the previous paragraph.

• Protecting Access to Medicare Act of 2014 ("PAMA") has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

• without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.

• In addition, there is an increasing focus by U.S. and international regulators, investors, customers, and other stakeholders on environmental, social and governance ("ESG") matters. Complying with new laws or regulations concerning sustainability matters, climate related matters or other ESG matters…